Regn2477+regn1033    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
15Inclusion body myositis1

15. Inclusion body myositis    [ 39 clinical trials,   32 drugs,   (DrugBank: 11 drugs),   11 drug target genes,   119 drug target pathways]
Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 39 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03710941
(ClinicalTrials.gov)
February 19, 201915/10/2018Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisSporadic Inclusion Body MyositisDrug: REGN2477+REGN1033;Drug: Matching placeboRegeneron PharmaceuticalsNULLWithdrawn45 Years75 YearsAll0Phase 2NULL